Accelerating CKD And IBS-C Demand Will Transform Treatment Landscape

AN

AnalystHighTarget

Not Invested

Community Contributor

Published

23 Aug 25

Updated

06 Apr 26

Views

46

06 Apr

US$6.05

AnalystHighTarget's Fair Value

US$19.00

68.2% undervalued

1Y

66.7%

7D

6.4%

Loading

1Y

66.7%

7D

6.4%

Author's Valuation

US$1968.2% undervalued

AnalystHighTarget Fair Value

Shared on 06 Apr 26

ARDX: Extended Patent Runway And 2029 Revenue Guidance Will Support Repricing

Ardelyx's consensus analyst price target has moved higher toward $19, with the shift largely tied to stronger Ibsrela revenue guidance, extended patent protection into the 2040s, and analyst expectations reflected in updated P/E, growth, and margin assumptions. Analyst Commentary Bullish analysts have been revising their views higher, with a series of price target increases and rating upgrades clustering around Ardelyx's updated Ibsrela guidance and extended patent protection.

8 views

Shared on 09 Mar 26

ARDX: Extended Patent Runway And 2029 Revenue Outlook Will Drive Bullish Repricing

Ardelyx's analyst price target has moved higher, with several firms lifting their views into a $14 to $19 range. Analysts highlight extended patent protection on key assets, updated Ibsrela revenue guidance that includes targets of $410m to $430m in FY26 and $1b by 2029, and a stronger outlook for the broader product portfolio and cash position.

6 views

Shared on 22 Feb 26

Fair value Increased 19%

ARDX: Extended Patent Runway And 2029 Revenue Path Will Support Bullish Outlook

The analyst fair value estimate for Ardelyx has shifted from $16.00 to $19.00, as analysts factor in higher projected revenue, updated profitability assumptions, and extended intellectual property protection highlighted in recent research notes. Analyst Commentary Recent Street research on Ardelyx has leaned firmly positive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings after management updates and new patent developments.

6 views

Shared on 25 Dec 25

Fair value Increased 6.67%

ARDX: Long-Term Profitability Improvements Will Drive Stronger Bullish Outlook

Analysts have raised their price target on Ardelyx from 15 dollars to 16 dollars. This reflects slightly stronger expectations for long term revenue growth, improved profitability, and a modestly lower future earnings multiple despite a higher discount rate.

13 views

Valuator

Company Info

Notes

AnalystHighTarget Fair Value

US$19

68.2% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

$

Forecast revenue growth rate

24.55%

Historical revenue growth rate

59.63%

Biotech revenue growth rate

10.74%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.42%

Calculation

US$425.81m

Earnings '29

x

14.57x

PE Ratio '29

=

US$6.21b

Market Cap '29

US$6.21b

Market Cap '29

/

264.14m

No. shares '29

=

US$23.49

Share Price '29

US$23.49 Share Price '29

Discounted to 2026 @ 7.35% p.a.

=

US$18.99

Fair Value '26